Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price Target Cut by Oppenheimer

Posted by Francis Steltz on Nov 10th, 2026

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) had its price objective cut by stock analysts at Oppenheimer from $85.00 to $70.00 in a report issued on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Oppenheimer‘s price target would indicate a potential upside of 145.56% from the stock’s previous close.

IONS has been the topic of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a report on Thursday, October 15th. Morgan Stanley dropped their price target on shares of Ionis Pharmaceuticals from $110.00 to $104.00 and set an “overweight” rating for the company in a research note on Tuesday, September 8th. Needham & Company LLC cut their price target on shares of Ionis Pharmaceuticals from $86.00 to $54.00 and set a “buy” rating for the company in a report on Monday. The Goldman Sachs Group reduced their price target on shares of Ionis Pharmaceuticals from $69.00 to $56.00 and set a “neutral” rating on the stock in a research report on Tuesday, September 8th. Finally, Citigroup reiterated a “buy” rating on shares of Ionis Pharmaceuticals in a report on Wednesday, October 21st. Nineteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $82.71.

Read Our Latest Research Report on IONS

Ionis Pharmaceuticals Trading Down 8.0%

Shares of NASDAQ IONS traded down $2.49 during trading on Tuesday, hitting $28.51. 2,067,998 shares of the company were exchanged, compared to its average volume of 2,742,501. Ionis Pharmaceuticals has a 12-month low of $27.75 and a 12-month high of $86.74. The company has a debt-to-equity ratio of 3.07, a quick ratio of 7.73 and a current ratio of 7.89. The company has a fifty day moving average price of $46.20 and a 200-day moving average price of $65.63. The firm has a market capitalization of $4.74 billion, a PE ratio of -8.25 and a beta of 0.43.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.57. Ionis Pharmaceuticals had a negative net margin of 64.76% and a negative return on equity of 111.08%. The firm had revenue of $242.72 million during the quarter, compared to analyst estimates of $178.17 million. During the same quarter in the prior year, the firm posted ($0.80) earnings per share. Ionis Pharmaceuticals’s quarterly revenue was up 54.8% on a year-over-year basis. As a group, equities research analysts expect that Ionis Pharmaceuticals will post -3.62 EPS for the current year.

Insider Transactions at Ionis Pharmaceuticals

In related news, EVP Shannon Devers sold 1,357 shares of the business’s stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $43.54, for a total value of $59,083.78. Following the sale, the executive vice president directly owned 17,811 shares in the company, valued at approximately $775,490.94. The trade was a 7.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 1.81% of the company’s stock.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Alyeska Investment Group L.P. lifted its holdings in shares of Ionis Pharmaceuticals by 199.7% in the 2nd quarter. Alyeska Investment Group L.P. now owns 1,417,916 shares of the company’s stock worth $112,427,000 after acquiring an additional 944,766 shares during the last quarter. Pictet Asset Management Holding SA boosted its position in shares of Ionis Pharmaceuticals by 21.7% during the 3rd quarter. Pictet Asset Management Holding SA now owns 1,944,020 shares of the company’s stock worth $87,249,000 after purchasing an additional 347,022 shares during the period. Bank of America Corp DE acquired a new stake in Ionis Pharmaceuticals in the 2nd quarter valued at approximately $62,718,000. Groupama Asset Managment raised its position in Ionis Pharmaceuticals by 7.5% in the first quarter. Groupama Asset Managment now owns 824,540 shares of the company’s stock valued at $61,915,000 after purchasing an additional 57,651 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Ionis Pharmaceuticals during the second quarter worth $54,253,000. 93.86% of the stock is currently owned by institutional investors and hedge funds.

More Ionis Pharmaceuticals News

Here are the key news stories impacting Ionis Pharmaceuticals this week:

Positive Sentiment: Ionis reported third-quarter revenue of about $243 million, up roughly 55% year over year and above expectations. Its quarterly loss was also narrower than analysts had forecast. Read More.
Positive Sentiment: DAWNZERA sales grew 40% to $37 million, providing a positive commercial update amid weakness in TRYNGOLZA’s launch. Read More.
Negative Sentiment: Ionis cut its 2026 TRYNGOLZA sales outlook to approximately $50 million, down from its prior $100 million–$110 million target. The company cited slower-than-expected uptake and competitive pressure, undermining expectations for the drug’s commercial potential. Read More.
Negative Sentiment: Ionis guided to 2026 revenue of $875 million–$900 million, below the roughly $921 million consensus estimate, adding to concerns about near-term growth. Read More.
Negative Sentiment: Law firms announced investigations into potential investor claims related to Ionis, adding a legal overhang following the sales forecast reduction. These announcements concern potential claims and do not establish wrongdoing. Read More.
Negative Sentiment: HC Wainwright and Needham lowered their price targets to $70 and $54, respectively, although both maintained Buy ratings. Read More. · Read More.

About Ionis Pharmaceuticals

(Get Free Report)

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases.

Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.